Latest Biotech News

A landmark cohort study published in npj Parkinson’s Disease reveals that pathological changes in skin-accessible cutaneous nerve fibers provide novel insights into Parkinson’s disease and...

Novo Nordisk advances its obesity pipeline by planning late-stage clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist. Following promising phase 2 data indicating substantial...

ADC Therapeutics announced a 30% workforce reduction and the closure of its UK R&D facility after halting development of multiple preclinical and clinical candidates due to limited efficacy and...

A research team led by W. Zeng and colleagues has developed a magnetic soft millirobot that can both navigate and sense environmental variables simultaneously. Utilizing a polymer matrix with...

Recent cohort studies published in npj Parkinson’s Disease reveal key alterations in cutaneous nerve fibers in Parkinson’s disease (PD) and atypical parkinsonism. Using immunohistochemical...

The U.S. Food and Drug Administration has approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1 (CPS ≥1). This marks the first...

Anne Wojcicki, co-founder and former CEO of 23andMe, led a nonprofit, the TTAM Research Institute, which has secured a $305 million deal to acquire the majority of 23andMe’s assets after...

Novo Nordisk has announced plans to commence late-stage (phase 3) clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist designed for weight loss. This program includes both...

Researchers from Boston Children’s Hospital and collaborators have developed an accelerated method to generate vascular organoids from human induced pluripotent stem cells (iPSCs) by...

Multiomics approaches integrating genomics, transcriptomics, and proteomics are increasingly central to life sciences. Ultima Genomics and partners like Olink Proteomics have collaborated to...

Engineers at the University of California San Diego have developed an evaporative cooling technology using fiber membranes with controlled porosity to passively dissipate heat from electronics....

Immunai has partnered with the Parker Institute for Cancer Immunotherapy to generate a large-scale, clinically annotated single-cell gene expression dataset from over 1,000 cancer patients...

Clinical trials and real-world data increasingly harness artificial intelligence and digital biomarkers to refine psychiatric treatment strategies. AI tools offer psychiatrists improved...

The FDA approved pembrolizumab for resectable locally advanced head and neck cancer with PD-L1 expression, based on data from the KEYNOTE-689 phase 3 trial showing improved event-free survival and...

Johnson and Johnson reported a 100% objective response rate in relapsed/refractory large B-cell lymphoma patients with one prior therapy using its dual CD19/CD20-targeting CAR-T. The therapy...

After discontinuing its only clinical-stage candidate, ADC Therapeutics announced closure of its UK R&D facility and a 30% staff reduction. Several early programs were halted to focus resources on...

The FDA has approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, marking the first checkpoint inhibitor approval in the...

Johnson and Johnson released encouraging phase 1b data for their dual-targeting CD19/CD20 CAR-T therapy in relapsed or refractory large B-cell lymphoma patients. The objective response rate was...

Insmed mailed a $750 million follow-on public equity offering following positive clinical data in hypertension. The financing round highlights growing investor confidence fueled by clinical...

Former CEO Anne Wojcicki’s nonprofit, the TTAM Research Institute, won a second auction to acquire 23andMe’s assets for $305 million, surpassing Regeneron’s prior bid. Agreement includes...